For decades, the diagnosis of multiple myeloma required evidence of end-organ damage characterized by myeloma-defining events ...

2seventy bio investors were understandably happy this past week when Bristol Myers Squibb (BMS) agreed to acquire its partner in developing the blockbuster multiple myeloma drug Abecma ...